Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suhasini Iyer

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2003
Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouseJesus A Araujo, Lingzhong Meng, Aaron D Tward, et al.
Frontiers in Immunology|October 29, 2025
Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in an <i>in-vivo</i> model of xeno-GvHDGhenima Ahmil-Boiteau, Pranjali Dalvi, Kevin Dang, et al.
Mabs|April 5, 2021
TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHLHarbani K Malik-Chaudhry, Kirthana Prabhakar, Harshad S Ugamraj, et al.
Mabs|January 31, 2019
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodiesNathan D Trinklein, Duy Pham, Ute Schellenberger, et al.
The Journal of Biological Chemistry|May 7, 2010
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signalingJanet Jackman, Yongmei Chen, Arthur Huang, et al.
Mabs|July 22, 2022
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activityHarshad S Ugamraj, Kevin Dang, Laure-Hélène Ouisse, et al.
Journal for Immunotherapy of Cancer|June 5, 2021
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine releaseKevin Dang, Giulia Castello, Starlynn C Clarke, et al.
Scientific Reports|May 20, 2021
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cellsKatherine E Harris, Kyle J Lorentsen, Harbani K Malik-Chaudhry, et al.
Blood|August 10, 2007
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockadeWei Yu Lin, Qian Gong, Dhaya Seshasayee, et al.
Frontiers in Immunology|May 10, 2018
Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific AntibodiesKatherine E Harris, Shelley Force Aldred, Laura M Davison, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2003
Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouseJesus A Araujo, Lingzhong Meng, Aaron D Tward, et al.
Frontiers in Immunology|October 29, 2025
Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in an <i>in-vivo</i> model of xeno-GvHDGhenima Ahmil-Boiteau, Pranjali Dalvi, Kevin Dang, et al.
Mabs|April 5, 2021
TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHLHarbani K Malik-Chaudhry, Kirthana Prabhakar, Harshad S Ugamraj, et al.
Mabs|January 31, 2019
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodiesNathan D Trinklein, Duy Pham, Ute Schellenberger, et al.
The Journal of Biological Chemistry|May 7, 2010
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signalingJanet Jackman, Yongmei Chen, Arthur Huang, et al.
Mabs|July 22, 2022
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activityHarshad S Ugamraj, Kevin Dang, Laure-Hélène Ouisse, et al.
Journal for Immunotherapy of Cancer|June 5, 2021
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine releaseKevin Dang, Giulia Castello, Starlynn C Clarke, et al.
Scientific Reports|May 20, 2021
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cellsKatherine E Harris, Kyle J Lorentsen, Harbani K Malik-Chaudhry, et al.
Blood|August 10, 2007
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockadeWei Yu Lin, Qian Gong, Dhaya Seshasayee, et al.
Frontiers in Immunology|May 10, 2018
Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific AntibodiesKatherine E Harris, Shelley Force Aldred, Laura M Davison, et al.
Pageof 4